June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Histological evaluation of early diabetic neurodegenertion in Zucker Diabetic Fatty (ZDF) Rats
Author Affiliations & Notes
  • Akos Lukats
    Human Morphology & Dev Biol, Semmelweis University, Budapest, Hungary
  • Klaudia Szabo
    Human Morphology & Dev Biol, Semmelweis University, Budapest, Hungary
  • Arnold Szabo
    Human Morphology & Dev Biol, Semmelweis University, Budapest, Hungary
  • Anna Enzsoly
    Dept. of Ophthalmology, Semmelweis University, Budapest, Hungary
  • Bulcsu Dekany
    Human Morphology & Dev Biol, Semmelweis University, Budapest, Hungary
  • Tamas Radovits
    Heart Center, Semmelweis University, Budapest, Hungary
  • Csaba Mátyás
    Heart Center, Semmelweis University, Budapest, Hungary
  • Kornelia Lenke Laurik
    Dept. of Ophthalmology, Semmelweis University, Budapest, Hungary
  • Gabor Mark Somfai
    Dept. of Ophthalmology, Semmelweis University, Budapest, Hungary
  • Agoston Szel
    Human Morphology & Dev Biol, Semmelweis University, Budapest, Hungary
  • Footnotes
    Commercial Relationships Akos Lukats, None; Klaudia Szabo, None; Arnold Szabo, None; Anna Enzsoly, None; Bulcsu Dekany, None; Tamas Radovits, None; Csaba Mátyás, None; Kornelia Lenke Laurik, None; Gabor Somfai, None; Agoston Szel, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4711. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Akos Lukats, Klaudia Szabo, Arnold Szabo, Anna Enzsoly, Bulcsu Dekany, Tamas Radovits, Csaba Mátyás, Kornelia Lenke Laurik, Gabor Mark Somfai, Agoston Szel; Histological evaluation of early diabetic neurodegenertion in Zucker Diabetic Fatty (ZDF) Rats. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4711.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Literature data indicates that in diabetes retinal dysfunctions related to neural retinal alterations exist prior to clinically detectable vasculopathy, however, the histological background behind these functional deficits is largely unknown. Previously, a detailed description about the histology of the outer and inner retina was given in streptozocin (STZ) induced (type 1) diabetic rats, where neural retinal degeneration preceded apoptotic loss of cells. Here, we investigated the histopathology of the retina in early diabetes using Zucker Diabetic Fatty (ZDF) rats, a well-know model of type 2 diabetes.

Methods: The morphology, density and staining characteristics of the labeled cells were analyzed by immunohistochemistry after six months of diabetes, using cell-type specific antibodies.

Results: Glial reactivity was observed in all diabetic retinal specimens, manifested by strong GFAP upregulation. Marked outer segment degeneration was detected in rods and in the majority of M/L-cones, without an apparent decrease in the number of stained elements and without any major change in the expression of other photoreceptor specific markers like arrestin and transducin. An increase in the number of dual cones, coexpressing two photopigments was also visible. The immunoreactivity of parvalbumin (staining mostly AII amacrine cells) was markedly decreased and we detected a change in the number of PKC-α labeled amacrine and displaced amacrine cells. In contrast to these, most other markers used (including calretinin, recoverin, tyrosin hydroxylase, anti-Brn-3a, NeuN and calbindin) did not show any major alterations in the intensity of immunoreactivity or in the number of stained elements.

Conclusions: Overall, the retina of ZDF rats shows a surprising similarity to STZ induced type 1 diabetic rats, indicating that most of the changes are consequences of the high glucose levels while the lack of insulin does not play a decisive role in the development of histological alterations. The presence of early retinal degeneration raises the possibility that neuroprotective therapy in diabetic patients should be beneficial even prior to vasculopathy or overt loss of cells.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×